Exelixis, Inc. $EXEL Shares Purchased by Lingohr Asset Management GmbH

Lingohr Asset Management GmbH raised its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 1,258.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 284,022 shares of the biotechnology company’s stock after purchasing an additional 263,121 shares during the quarter. Exelixis comprises 2.8% of Lingohr Asset Management GmbH’s portfolio, making the stock its 4th largest holding. Lingohr Asset Management GmbH’s holdings in Exelixis were worth $11,730,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of EXEL. Winnow Wealth LLC acquired a new stake in shares of Exelixis in the third quarter valued at $1,017,000. Arizona State Retirement System grew its holdings in Exelixis by 4.3% during the third quarter. Arizona State Retirement System now owns 76,652 shares of the biotechnology company’s stock worth $3,166,000 after acquiring an additional 3,172 shares during the period. Impact Partnership Wealth LLC raised its position in Exelixis by 17.3% in the third quarter. Impact Partnership Wealth LLC now owns 9,788 shares of the biotechnology company’s stock worth $404,000 after acquiring an additional 1,443 shares in the last quarter. Foundations Investment Advisors LLC acquired a new stake in Exelixis in the 3rd quarter valued at about $322,000. Finally, Ruffer LLP lifted its holdings in Exelixis by 7.1% in the 3rd quarter. Ruffer LLP now owns 81,696 shares of the biotechnology company’s stock valued at $3,374,000 after acquiring an additional 5,386 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Down 2.2%

Shares of NASDAQ:EXEL opened at $41.36 on Friday. The company’s fifty day moving average is $43.76 and its two-hundred day moving average is $41.06. The company has a market cap of $11.09 billion, a P/E ratio of 17.45, a price-to-earnings-growth ratio of 0.76 and a beta of 0.40. Exelixis, Inc. has a 12-month low of $32.38 and a 12-month high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The business had revenue of $597.76 million for the quarter, compared to the consensus estimate of $590.04 million. During the same quarter in the previous year, the company posted $0.47 earnings per share. Exelixis’s revenue for the quarter was up 10.8% compared to the same quarter last year. Equities research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insider Activity at Exelixis

In other Exelixis news, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the completion of the sale, the director owned 1,189,228 shares of the company’s stock, valued at $51,790,879.40. This trade represents a 7.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 34,187 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $41.88, for a total value of $1,431,751.56. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 245,235 shares of company stock valued at $10,490,600. Company insiders own 2.82% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. HC Wainwright lifted their price objective on shares of Exelixis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday. TD Cowen restated a “buy” rating on shares of Exelixis in a research report on Wednesday, November 5th. Guggenheim cut Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research note on Thursday, January 22nd. Finally, UBS Group set a $41.00 target price on Exelixis in a report on Monday, January 5th. Eleven investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $45.95.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.